Headlines about Persimmon in the news last year must have made their PR people want to find the nearest wall to bang their head against. One BBC headline from December 2019 was ‘Builder Persimmon lacks minimum house standards, report finds.’ Another headline in The Times in March of that year read ‘Bonus row Persimmon chief... Continue Reading →
Updates from portfolio holdings: Persimmon, AstraZeneca, Synthomer and WPP
Today was always going to be a busy day for my portfolio in a busy day of company announcements. It was a mixed bag but AstraZeneca once again was the standout company with a great update and it’s little surprise to see the share price rise even further. Persimmon (LSE: PSN) Persimmon which has started... Continue Reading →